Liraglutide Shows Promise for Treating Obesity in Children as Young as Six
Novo Nordisk NVO is reporting encouraging results for its weight-loss drug, liraglutide, in young children. In a comprehensive, well-funded study, kids ages six to twelve who received a once-daily injectable form of liraglutide for a year saw, on average, a 7.4% reduction in body mass index compared with peers given a placebo. That’s a meaningful shift over a relatively short period, especially at this age.
Why This Study Matters
The clinical trial enrolled 82 children, and the results raise the possibility that liraglutide could become the first obesity treatment designed specifically for children under twelve. Martin Holst Lange, Novo Nordisk’s head of development, said the company plans to seek approvals from both the U.S. Food and Drug Administration and the European Medicines Agency. If successful, it would mark a notable step forward for pediatric care.
Childhood Obesity, Plainly Stated
About one in five children live with obesity today. Because childhood obesity is a strong predictor of adult obesity, safe and effective options early in life matter. Lange underscored that point, framing liraglutide as a potentially useful tool for clinicians and families who have had limited choices.
What the Trial Found—and What Comes Next
The study, led by Claudia Fox at the University of Minnesota Medical School, also highlighted a gap: there are currently no approved medications that specifically treat obesity in children under twelve. Alongside liraglutide, Novo Nordisk is studying semaglutide—the active ingredient in Ozempic and Wegovy—for younger adolescents. Semaglutide already has approval for use in those aged twelve and older.
What to Watch: Side Effects and Stopping the Drug
While the findings are promising, caution is warranted. Nausea and vomiting were reported among participants taking liraglutide. Another practical consideration: weight tended to return quickly after stopping treatment. Importantly, the study did not find differences in growth, bone age, or pubertal development between the liraglutide and placebo groups over the study period.
Context: A Market Under Scrutiny
Novo Nordisk’s update lands amid intense attention on weight-loss drugs. Authorities and consumers have raised alarms over counterfeit products, including copies of Ozempic, with criminal schemes producing fraudulent batches that have drawn scrutiny from regulators worldwide. Supply, safety, and authenticity remain active concerns.
Semaglutide’s Potential Beyond Weight
Research into semaglutide continues to explore effects that may extend beyond weight loss. Emerging studies suggest possible benefits for conditions such as heart failure, arthritis, Alzheimer’s disease, and some cancers. That work is ongoing, but it’s shaping how clinicians view the broader therapeutic profile of these medicines.
Demand, Prices, and New Entrants
Demand for weight-loss medications has surged. In response, companies like Hims & Hers Health Inc. HIMS are weighing lower-cost options as prices rise and supply tightens for in-demand drugs. Whether those alternatives remain viable over time is an open question, especially as major manufacturers scale up production to meet demand.
Eli Lilly’s Competitive Push
Eli Lilly LLY has moved to offer discounted versions of its appetite-suppressing medicines, Mounjaro and Zepbound. The effort aims to counter copycat products and address ongoing debate about shortages and access.
Stock Snapshot and Outlook
Recently, Novo Nordisk shares closed at $129.78, down 1.61% on the day. After-hours trading showed a modest rebound of 0.54%. Year to date, the stock is up about 27.10%, reflecting investor confidence in the company’s research and development pipeline.
Frequently Asked Questions
How much did children’s BMI change on liraglutide?
On average, children six to twelve years old receiving liraglutide for a year saw a 7.4% reduction in body mass index compared with those on placebo.
Are there any approved obesity drugs for kids under 12?
No. According to the study led by Claudia Fox, there are currently no approved pharmaceutical treatments specifically for obesity in children under twelve.
What side effects were observed in the study?
The most commonly noted side effects were nausea and vomiting. The trial did not find differences in growth, bone age, or puberty between the treatment and control groups during the study period.
What happens after stopping liraglutide?
Weight tended to return quickly after discontinuing the drug, which suggests that continued treatment or other long-term strategies may be needed to maintain results.
Where do semaglutide and other competitors fit in?
Semaglutide, the active ingredient in Ozempic and Wegovy, is approved for those twelve and older and is being studied in younger adolescents. Meanwhile, companies like Hims & Hers and Eli Lilly are adjusting pricing and supply strategies amid strong demand and concerns about counterfeits.
